Fig. 2From: The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based studyNumber of prevalent cases of CML, number of TKI users (numbers on graphic area) and number of posological units (pills) of imatinib, dasatinib and nilotinib delivered per year by the hospital pharmacy to inpatients resident in the provinces of Modena and Reggio Emilia. Data from hospital pharmacy databasesBack to article page